Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes

NCT02650024 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2021-04-27

No results posted yet for this study

Summary

This study observes the effects of newly developed direct-acting antiviral (DAA) treatments on the central nervous system (CNS) of individuals with chronic Hepatitis C (HCV). The goals of this study are to determine the CNS impact of curing chronic HCV disease with newly established DAA therapies and how HIV alters this relationship.

Conditions

  • Hepatitis C
  • Human Immunodeficiency Virus

Sponsors & Collaborators

Principal Investigators

  • Ajay Bharti, M.D. · UCSD

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2021-04-30
Completion
2021-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02650024 on ClinicalTrials.gov